Home > PE Ratio > AUROBINDO PHARMA

AUROBINDO PHARMA
PE (Price/Earnings) Ratio

The Current P/E Ratio of AUROBINDO PHARMA is 22.93.

Share Price ₹1,394.7Nov 06,2024
Market Cap ₹81,001.3 Cr
Earnings-TTM₹3,533.2 CrTTM-Consolidated Results
Price/Earnings22.93xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for AUROBINDO PHARMA
Please provide your vote to see the results

Definition & Calculation of PE (Price/Earnings) ratio of AUROBINDO PHARMA

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of AUROBINDO PHARMA is calculated as :

Current Market Cap [ ₹81,001.3 Cr] as on Nov 06,2024

(/) Earnings [ ₹3,533.2 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 22.93x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for AUROBINDO PHARMA , the investors are currently willing to pay 22.93 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AUROBINDO PHARMA !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of AUROBINDO PHARMA over the last five years.

Historical PE (Price/Earnings) ratio chart of AUROBINDO PHARMA


PE Ratio Performance Analysis for AUROBINDO PHARMA

- AUROBINDO PHARMA 's latest p/e ratio is 22.93x.

- AUROBINDO PHARMA 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 13.77x.

- AUROBINDO PHARMA 's operated at median p/e ratio of 14.8x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, AUROBINDO PHARMA 's p/e ratio peaked in Mar2024 at 20.12x.

- AUROBINDO PHARMA 's p/e ratio hit its five-year low in Mar2020 of 8.51x.


How does AUROBINDO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
AUROBINDO PHARMA 3,533.2222.9381,001.3
SUN PHARMACEUTICAL INDUSTRIES LTD11,136.5039.37438,418.0
CIPLA LTD4,485.2228.71128,755.0
DR REDDYS LABORATORIES LTD5,406.8020.11108,720.0
ZYDUS LIFESCIENCES LTD4,181.9023.94100,120.0
DIVIS LABORATORIES LTD1,674.0094.19157,680.0
MANKIND PHARMA LTD2,124.8651.85110,181.0
TORRENT PHARMACEUTICALS LTD1,802.0060.28108,624.0
LUPIN LTD2,287.7843.1798,759.4
ABBOTT INDIA LTD1,238.9949.9361,867.8
ALKEM LABORATORIES LTD2,073.8933.7469,979.6

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AUROBINDO PHARMA 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 20.11x
Max industry PE 94.19x
Median industry PE 39.37x
Average industry PE 42.57x



You may also like the below Video Courses